Articles from Sensorion

Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
By Sensorion · Via Business Wire · December 27, 2024
Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
By Sensorion · Via Business Wire · December 18, 2024
Sensorion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Regulatory News:
By Sensorion · Via Business Wire · December 3, 2024
Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024
Regulatory News:
By Sensorion · Via Business Wire · November 6, 2024
Sensorion Announces its Participation in the 31st Annual Congress of the European Society of Gene and Cell Therapy and the Presentation of Several Posters on GJB2-GT
Regulatory News:
By Sensorion · Via Business Wire · October 17, 2024
Sensorion Announces Webconference for Retail Shareholders on October 10, 2024
Regulatory News:
By Sensorion · Via Business Wire · September 26, 2024
Sensorion Announces the Availability of its Half Year 2024 Report
Regulatory News:
By Sensorion · Via Business Wire · September 23, 2024
Sensorion Reports New Positive Clinical Results Presented at the World Congress of Audiology
Regulatory News:
By Sensorion · Via Business Wire · September 23, 2024
Sensorion Announces New Positive Clinical Data Across its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris
Regulatory News:
By Sensorion · Via Business Wire · September 20, 2024
Sensorion Reports 2024 First Half Results and Highlights Recent Updates
Regulatory News:
By Sensorion · Via Business Wire · September 18, 2024
Sensorion Announces Its Participation in the 59th Annual Inner Ear Biology Workshop
Regulatory News:
By Sensorion · Via Business Wire · September 12, 2024
Sensorion Announces its Participation in the World Congress of Audiology in September 2024 in Paris and will Lead a Symposium on Medical Advances in the Field of Hearing Loss
Regulatory News:
By Sensorion · Via Business Wire · September 2, 2024
Sensorion Announces its Participation in Stifel's Biotech Summer Summit
Regulatory News:
By Sensorion · Via Business Wire · August 5, 2024
Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
Regulatory News:
By Sensorion · Via Business Wire · July 23, 2024
Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss
Regulatory News:
By Sensorion · Via Business Wire · July 15, 2024
Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer
Regulatory News:
By Sensorion · Via Business Wire · June 27, 2024
Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies
Regulatory News:
By Sensorion · Via Business Wire · June 20, 2024
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
By Sensorion · Via Business Wire · May 30, 2024
Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024
Regulatory News:
By Sensorion · Via Business Wire · May 28, 2024
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 29, 2024
Regulatory News:
By Sensorion · Via Business Wire · May 7, 2024
Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
Regulatory News:
By Sensorion · Via Business Wire · April 26, 2024
Sensorion Announces its Participation in the Van Lanschot Kempen's Life Sciences Conference
Regulatory News:
By Sensorion · Via Business Wire · April 10, 2024
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
Regulatory News:
By Sensorion · Via Business Wire · April 8, 2024
Sensorion Announces the Availability of Its Letter to Shareholders
Regulatory News:
By Sensorion · Via Business Wire · March 21, 2024
Sensorion Announces its Participation in the Annual Bioprocessing Summit Europe
Regulatory News:
By Sensorion · Via Business Wire · March 15, 2024
Sensorion Announces the Availability of its Financial Report for 2023
Regulatory News:
By Sensorion · Via Business Wire · March 14, 2024
Sensorion Reports Full-Year 2023 Financial Results and Business Update
Regulatory News:
By Sensorion · Via Business Wire · March 14, 2024
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation
Regulatory News:
By Sensorion · Via Business Wire · March 11, 2024
Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results
Regulatory News:
By Sensorion · Via Business Wire · March 6, 2024
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference
Regulatory News:
By Sensorion · Via Business Wire · February 29, 2024
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
Regulatory News:
By Sensorion · Via Business Wire · February 9, 2024
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
Regulatory News:
By Sensorion · Via Business Wire · February 1, 2024
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting
Regulatory News:
By Sensorion · Via Business Wire · January 29, 2024
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
Regulatory News:
By Sensorion · Via Business Wire · January 25, 2024
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
Regulatory News:
By Sensorion · Via Business Wire · January 19, 2024
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years
Regulatory News:
By Sensorion · Via Business Wire · January 5, 2024
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
By Sensorion · Via Business Wire · December 21, 2023
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
Regulatory News:
By Sensorion · Via Business Wire · December 18, 2023
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer
Regulatory News:
By Sensorion · Via Business Wire · December 12, 2023
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
Regulatory News:
By Sensorion · Via Business Wire · November 30, 2023
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
Regulatory News:
By Sensorion · Via Business Wire · November 23, 2023
Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery’s Life Sciences Symposium
Regulatory News:
By Sensorion · Via Business Wire · October 25, 2023
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
Regulatory News:
By Sensorion · Via Business Wire · October 18, 2023
Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023
Regulatory News:
By Sensorion · Via Business Wire · September 26, 2023
Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023
Regulatory News:
By Sensorion · Via Business Wire · September 21, 2023
Sensorion Reports 2023 First Half Results
Regulatory News:
By Sensorion · Via Business Wire · September 20, 2023
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
Regulatory News:
By Sensorion · Via Business Wire · July 19, 2023
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Regulatory News:
By Sensorion · Via Business Wire · July 10, 2023
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
By Sensorion · Via Business Wire · July 5, 2023
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
By Sensorion · Via Business Wire · June 19, 2023
Sensorion to Host Key Opinion Leader Webinar on July 5, 2023; Confirms Upcoming Key Milestones
Regulatory News:
By Sensorion · Via Business Wire · June 7, 2023
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
By Sensorion · Via Business Wire · May 25, 2023
Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting
Regulatory News:
By Sensorion · Via Business Wire · May 11, 2023
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023
Regulatory News:
By Sensorion · Via Business Wire · May 3, 2023
Sensorion to Host a Symposium during ISIET’s International Symposium on Inner Ear Therapeutics on April 30, 2023
Regulatory News:
By Sensorion · Via Business Wire · April 24, 2023
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
By Sensorion · Via Business Wire · April 18, 2023
Sensorion Announces Candidate Selection for GJB2 Gene Therapy Program
Regulatory News:
By Sensorion · Via Business Wire · April 6, 2023
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
Regulatory News:
By Sensorion · Via Business Wire · March 31, 2023
Sensorion Announces the Publication of Its 2022 Annual Financial Report
Regulatory News:
By Sensorion · Via Business Wire · March 30, 2023
Sensorion Reports Full-Year 2022 Financial Results and Business Update
Regulatory News:
By Sensorion · Via Business Wire · March 16, 2023
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease
Regulatory News:
By Sensorion · Via Business Wire · March 14, 2023
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
Regulatory News:
By Sensorion · Via Business Wire · March 13, 2023
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
Regulatory News:
By Sensorion · Via Business Wire · March 7, 2023
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer
Regulatory News:
By Sensorion · Via Business Wire · February 27, 2023
Sensorion announces R&D Day focusing on its Gene Therapy programs
Regulatory News:
By Sensorion · Via Business Wire · February 21, 2023
Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting
Regulatory News:
By Sensorion · Via Business Wire · February 2, 2023
Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear
Regulatory News:
By Sensorion · Via Business Wire · January 31, 2023
Sensorion Will Take Part in a Press Conference Launching the Annual UNESCO Week of Sound
Regulatory News:
By Sensorion · Via Business Wire · January 5, 2023
Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
Regulatory News:
By Sensorion · Via Business Wire · January 3, 2023
Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting in San Francisco
Regulatory News:
By Sensorion · Via Business Wire · December 5, 2022
Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration
Regulatory News:
By Sensorion · Via Business Wire · November 30, 2022
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
Regulatory News:
By Sensorion · Via Business Wire · November 7, 2022
Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France
Regulatory News:
By Sensorion · Via Business Wire · October 24, 2022
Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022
Regulatory News:
By Sensorion · Via Business Wire · October 6, 2022
Sensorion to Participate in Various Upcoming Investor Conferences
Regulatory News:
By Sensorion · Via Business Wire · September 26, 2022